ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa
April 10, 2024 05:03 ET
|
ViGeneron GmbH
VG901 is the first and only clinical-stage therapy designed to deliver a functional CNGA1 gene to retinal photoreceptor target cells in retinitis pigmentosa patientsVG901, using ViGeneron’s...